Retail Investors Who Own 46% Along With Institutions Invested in Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Saw Increase in Their Holdings Value Last Week
Retail Investors Who Own 46% Along With Institutions Invested in Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Saw Increase in Their Holdings Value Last Week
Key Insights
關鍵見解
- Henan Lingrui Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- 50% of the business is held by the top 25 shareholders
- Institutional ownership in Henan Lingrui Pharmaceutical is 29%
- 河南靈瑞製藥擁有大量散戶投資者的所有權,這表明關鍵決策受廣大公衆股東的影響
- 50% 的業務由前 25 名股東持有
- 河南凌瑞藥業的機構所有權爲29%
To get a sense of who is truly in control of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285), it is important to understand the ownership structure of the business. With 46% stake, retail investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
要了解誰真正控制了河南凌瑞藥業有限公司(SHSE: 600285),了解業務的所有權結構非常重要。散戶投資者擁有該公司的最大股份,擁有46%的股份。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。
While retail investors were the group that benefitted the most from last week's CN¥496m market cap gain, institutions too had a 29% share in those profits.
儘管散戶投資者是從上週4.96億元人民幣的市值增長中受益最大的群體,但機構在這些利潤中也佔有29%的份額。
Let's delve deeper into each type of owner of Henan Lingrui Pharmaceutical, beginning with the chart below.
讓我們從下圖開始,深入研究河南凌瑞製藥的每種所有者。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240310/0-291dad98a4ed91cf809619f303f2b02f-0-28dd03dff550485d4563de407edc08a8.png/big)
What Does The Institutional Ownership Tell Us About Henan Lingrui Pharmaceutical?
關於河南靈瑞藥業,機構所有權告訴我們什麼?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。
Henan Lingrui Pharmaceutical already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Henan Lingrui Pharmaceutical's earnings history below. Of course, the future is what really matters.
河南靈瑞製藥已經在股份登記處設立了機構。事實上,他們擁有該公司可觀的股份。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這一事實,因爲機構有時會像所有人一樣進行不良投資。如果多家機構同時改變對股票的看法,你可能會看到股價快速下跌。因此,值得在下面查看河南凌瑞製藥的收益記錄。當然,未來才是真正重要的。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240310/0-291dad98a4ed91cf809619f303f2b02f-1-6e42baffb6545ee9c61ed4298f65455c.png/big)
Henan Lingrui Pharmaceutical is not owned by hedge funds. Henan Lingrui Group Co., Ltd. is currently the largest shareholder, with 22% of shares outstanding. For context, the second largest shareholder holds about 4.9% of the shares outstanding, followed by an ownership of 4.5% by the third-largest shareholder. Additionally, the company's CEO Wei Xiong directly holds 0.6% of the total shares outstanding.
河南靈瑞製藥不歸對沖基金所有。河南凌銳集團有限公司目前是最大股東,已發行股份的22%。就背景而言,第二大股東持有約4.9%的已發行股份,其次是第三大股東持有4.5%的所有權。此外,該公司首席執行官熊偉直接持有已發行股份總額的0.6%。
Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.
我們的研究表明,前25名股東共同控制的公司股份不到一半,這意味着該公司的股票分佈廣泛,沒有占主導地位的股東。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。分析師對該股的報道很少,但報道不多。因此,它還有獲得更多報道的餘地。
Insider Ownership Of Henan Lingrui Pharmaceutical
河南凌瑞藥業的內部所有權
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
儘管內部人士的確切定義可能是主觀的,但幾乎每個人都認爲董事會成員是內部人士。公司管理層對董事會負責,後者應代表股東的利益。值得注意的是,有時高層管理人員自己也是董事會成員。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。
Shareholders would probably be interested to learn that insiders own shares in Henan Lingrui Pharmaceutical Co., Ltd.. This is a big company, so it is good to see this level of alignment. Insiders own CN¥171m worth of shares (at current prices). Most would say this shows alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.
股東們可能會有興趣得知內部人士擁有河南凌瑞製藥有限公司的股份。這是一家大公司,因此很高興看到這種一致性。內部人士擁有價值1.71億元人民幣的股票(按當前價格計算)。大多數人會說,這表明股東和董事會之間的利益一致。儘管如此,可能值得檢查一下這些內部人士是否一直在出售。
General Public Ownership
一般公有制
The general public, who are usually individual investors, hold a 46% stake in Henan Lingrui Pharmaceutical. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
公衆通常是個人投資者,持有河南凌瑞製藥46%的股份。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。
Private Company Ownership
私人公司所有權
Our data indicates that Private Companies hold 24%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
我們的數據表明,私人公司持有該公司24%的股份。可能值得對此進行更深入的研究。如果關聯方,例如內部人士,對其中一傢俬營公司感興趣,則應在年度報告中披露。私營公司也可能對公司有戰略利益。
Next Steps:
後續步驟:
It's always worth thinking about the different groups who own shares in a company. But to understand Henan Lingrui Pharmaceutical better, we need to consider many other factors. For example, we've discovered 1 warning sign for Henan Lingrui Pharmaceutical that you should be aware of before investing here.
擁有公司股份的不同群體總是值得考慮的。但是,要更好地了解河南凌瑞藥業,我們需要考慮許多其他因素。例如,我們發現了河南凌瑞製藥的1個警告信號,在投資之前你應該注意這個信號。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
歸根結底,未來是最重要的。您可以訪問這份關於公司分析師預測的免費報告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。